PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)David S.P. Tan, Line Bjørge, Tuan Zea Tan et al.|International Journal of Gynecological Cancer|2023Cited by 1